Gilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales

Needham upgraded Gilead Sciences (GILD) to a Buy rating with a $133 price target, citing strong physician support and significant sales potential for its recently FDA-approved and EMA-recommended HIV PrEP drug, Yeztugo (lenacapavir). As the first and only twice-yearly PrEP option, Yeztugo is projected by Needham to generate $4.1 billion in sales by 2030 and $6.4 billion by 2035, exceeding current consensus expectations by 10% and 20% respectively, positioning it as a crucial growth driver for Gilead given its high reliance on HIV drug revenue.

Analysis

Gilead Sciences (GILD) has received a significant vote of confidence from Needham, which upgraded the stock from Hold to Buy with a $133 price target. This bullish revision is directly attributable to the commercial potential of Yeztugo (lenacapavir), the company's new HIV pre-exposure prophylaxis (PrEP) treatment. Yeztugo's key competitive advantage is its dosing schedule; as the first and only twice-yearly option, it offers a substantial convenience improvement over existing daily oral therapies. This advantage is supported by strong physician feedback and robust clinical data from the PURPOSE 1 and 2 trials, which demonstrated superior efficacy with over 99.9% of participants remaining HIV-negative. The drug has secured FDA approval in the U.S. and received a positive recommendation from the EMA's CHMP for European approval, which would also grant an additional year of market exclusivity. Needham's financial models project Yeztugo could generate $4.1 billion in sales by 2030 and $6.4 billion by 2035, figures that are 10% and 20% above current consensus, respectively. With approximately 70% of Gilead's revenue already stemming from HIV drugs, Yeztugo is positioned to be a critical driver of future top-line growth, justifying the market's positive reaction, which saw the stock rise 2.75% to $116.31.

Key Decisions for Investors

• Given Yeztugo's superior clinical profile, favorable twice-yearly dosing, and strong regulatory momentum in both the US and EU, investors should consider this product a pivotal long-term growth catalyst for Gilead.
• Investors should closely monitor the initial sales ramp-up and market share capture of Yeztugo post-launch, as its ability to convert patients from daily oral PrEP will be the key validation for Needham's above-consensus revenue forecasts.
• The final European Commission decision expected later this year represents a significant near-term catalyst; a positive outcome would de-risk the European revenue stream and add a valuable year of market exclusivity, further strengthening the bull case.